Document is current
Any future updates will be listed below
-
Authors
Mitchell, Eleanor
Mattjie, Christian
Bestwick, Jonathan P.
Barros, Rodrigo C.
Schuh, Artur F.
Simonet, Cristina
Noyce, Alastair J.
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Finance Code 001)
- License Information
-
More Information
Article History
Received: 21 September 2024
Accepted: 20 March 2025
First Online: 4 April 2025
Competing interests
: Authors E.M., C.M., J.P.B., C.S., R.C.B. and A.F.S. declare no financial or non-financial competing interests. A.J.N. reports grants from Parkinson’s UK, Barts Charity, Cure Parkinson’s, National Institute for Health and Care Research, Innovate UK, Virginia Keiley benefaction, Solvemed, the Medical College of Saint Bartholomew’s Hospital Trust, Alchemab, Aligning Science Across Parkinson’s Global Parkinson’s Genetics Program (ASAP-GP2) and the Michael J Fox Foundation. A.J.N. reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Bial, Charco Neurotech, Alchemab, Sosei Heptares, Umedeor and Britannia. A.J.N. has share options in Umedeor. A.J.N. is an Associate Editor for the Journal of Parkinson’s Disease.
